
Angelini Pharma acquires Catalyst to enter US market
Brain health company Angelini Pharma has acquired biopharmaceutical company Catalyst Pharmaceuticals in a deal worth $4.1 billion. Angelini Pharma has agreed to acquire all outstanding shares of Catalyst for $31.50 per share in cash, worth an overall $4.1 billion, in a move that allows the company to enter the US market… Read More
